Design, synthesis, molecular modelling and biological evaluation of novel 6-amino-5-cyano-2-thiopyrimidine derivatives as potent anticancer agents against leukemia and apoptotic inducers

References

• Varmus H. The new era in cancer research. Science. 2006;312(5777):1162–1165.
   PubMed Web of Science ®Google Scholar
• Wang Z, Shi X-H, Wang J, Zhou T, Xu Y-Z, Huang T-T, Li Y-F, Zhao Y-L, Yang L, Yang S-Y, et al. Synthesis, structure–activity relationships and preliminary antitumor evaluation of benzothiazole-2-thiol derivatives as novel apoptosis inducers. Bioorg Med Chem Lett. 2011;21(4):1097–1101.
   PubMed Web of Science ®Google Scholar
• Hamdi A, Said E, A. Farahat A, A. A. El-Bialy S, A. M. Massoud M. Synthesis and in vivo antifibrotic activity of novel leflunomide analogues. LDDD. 2016;13(9):912–920.
   Google Scholar
• Du M, Chen W, Liu K, Wang L, Hu Y, Mao Y, Sun X, Luo Y, Shi J, Shao K, et al. The global burden of leukemia and its attributable factors in 204 countries and territories: findings from the Global Burden of Disease 2019 study and projections to 2030. J Oncol. 2022;2022:1612702–1612714.,.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH. Introduction and overview of the classification of myeloid neoplasms. WHO Classif Tumours Haematop Lymphoid Tissues. Published online 2008;2:439.
   Google Scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348.
   PubMed Web of Science ®Google Scholar
• Branca MA. Multi-kinase inhibitors create buzz at ASCO. Nat Biotechnol. 2005;23(6):639–639.
   PubMed Web of Science ®Google Scholar
• Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR, Mak TW. Targeting mitosis in cancer: emerging strategies. Mol Cell. 2015;60(4):524–536.
   PubMed Web of Science ®Google Scholar
• Cicenas J, Kalyan K, Sorokinas A, Jatulyte A, Valiunas D, Kaupinis A, Valius M. Highlights of the latest advances in research on CDK inhibitors. Cancers . 2014;6(4):2224–2242.
   PubMed Web of Science ®Google Scholar
• Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs. 2013;24(10):999–1006.
   PubMed Web of Science ®Google Scholar
• Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–257.
   PubMed Web of Science ®Google Scholar
• C Ubah O, M Wallace H. Cancer therapy: targeting mitochondria and other sub-cellular organelles. Curr Pharm Des. 2014;20(2):201–222.
   PubMed Web of Science ®Google Scholar
• McBride A, Houtmann S, Wilde L, Vigil C, Eischen CM, Kasner M, Palmisiano N. The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome. Front Oncol. 2019;9:192.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi Y-X, Sneed T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375–388.
   PubMed Web of Science ®Google Scholar
• Droin N, Guéry L, Benikhlef N, Solary E. Targeting apoptosis proteins in hematological malignancies. Cancer Lett. 2013;332(2):325–334.
   PubMed Web of Science ®Google Scholar
• Kitada S, Pedersen IM, Schimmer AD, Reed JC. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene. 2002;21(21):3459–3474.
   PubMed Web of Science ®Google Scholar
• Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92(1):81–94.
   PubMed Web of Science ®Google Scholar
• Jan R, Chaudhry G-E-S, . Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 2019;9(2):205–218.
   PubMed Web of Science ®Google Scholar
• Chen B, Lee JB, Kang H, Minden MD, Zhang L. Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. J Exp Clin Cancer Res. 2018;37:1–11.
   PubMed Web of Science ®Google Scholar
• Mohseni M, Uludag H, Brandwein JM. Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. Am J Blood Res. 2018;8(4):29–56.
   PubMed Web of Science ®Google Scholar
• Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016;43(8):723–737.
   PubMed Web of Science ®Google Scholar
• Sasada T, Kobayashi F, Sakai N, Konakahara T. An unprecedented approach to 4, 5-disubstituted pyrimidine derivatives by a ZnCl2-catalyzed three-component coupling reaction. Org Lett. 2009;11(10):2161–2164.
   PubMed Web of Science ®Google Scholar
• Zarenezhad E, Rad MNS, Mosslemin MH, Tabatabaee M, Behrouz S. Nano-MoO3 as a highly efficient heterogeneous catalyst for a one-pot synthesis of tetrahydropyrimidine derivatives in water. J Chem Res. 2014;38(10):607–610.
   Google Scholar
• Jain KS, Chitre TS, Miniyar PB. Biological and medicinal significance of pyrimidines. Curr Sci. 2006;90(6):793–803.
   Web of Science ®Google Scholar
• Kumar S, Deep A, Narasimhan B. A review on synthesis, anticancer and antiviral potentials of pyrimidine derivatives. CBC. 2019;15(3):289–303.
   Google Scholar
• Iraji A, Nouri A, Edraki N, Pirhadi S, Khoshneviszadeh M, Khoshneviszadeh M. One-pot synthesis of thioxo-tetrahydropyrimidine derivatives as potent $β$-glucuronidase inhibitor, biological evaluation, molecular docking and molecular dynamics studies. Bioorg Med Chem. 2020;28(7):115359.
   PubMed Web of Science ®Google Scholar
• Iraji A, Khoshneviszadeh M, Firuzi O, Khoshneviszadeh M, Edraki N. Novel small molecule therapeutic agents for Alzheimer disease: focusing on BACE1 and multi-target directed ligands. Bioorg Chem. 2020;97:103649.
   PubMed Web of Science ®Google Scholar
• Kurasaka C, Nishizawa N, Ogino Y, Sato A. Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil. ACS Omega. 2022;7(7):6046–6052.
   PubMed Web of Science ®Google Scholar
• Watanabe T. Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer. Breast Cancer. 2013;20(4):302–309.
   PubMed Web of Science ®Google Scholar
• Pastor N, Domínguez I, Orta ML, Campanella C, Mateos S, Cortés F. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res. 2012;738-739:45–51.
   PubMed Web of Science ®Google Scholar
• Li H-J, Wang Y, Li B-X, Yang Y, Guan F, Pang X-C, Li X. Construction and analysis of competing endogenous RNA network of MCF-7 breast cancer cells based on the inhibitory effect of 6-thioguanine on cell proliferation. Oncol Lett. 2020;21(1):1–1.
   PubMedGoogle Scholar
• Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol. 1998;42(4):313–318.
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Guy SP, Woodburn JR. ZD1839 (Iressa) an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62(20):5749–5754.
   PubMed Web of Science ®Google Scholar
• Chan WY, Lau PM, Yeung KW, Kong SK. The second generation tyrosine kinase inhibitor dasatinib induced eryptosis in human erythrocytes—An in vitro study. Toxicol Lett. 2018;295:10–21.
   PubMed Web of Science ®Google Scholar
• Tang B, Tang P, He J, Yang H, Li H. Characterization of the binding of a novel antitumor drug ibrutinib with human serum albumin: Insights from spectroscopic, calorimetric and docking studies. J Photochem Photobiol B. 2018;184:18–26.
   PubMed Web of Science ®Google Scholar
• Rossi G, Anastasia A, others Novel drugs in follicular lymphoma. Mediterr J Hematol Infect Dis. 2016;8(1):e2016061–e2016061.
   PubMedGoogle Scholar
• Yu M, Chen J, Xu Z, Yang B, He Q, Luo P, Yan H, Yang X. Development and safety of PI3K inhibitors in cancer. Arch Toxicol. 2023;97(3):635–650.
   PubMed Web of Science ®Google Scholar
• VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the cyclin D–CDK4/6 axis for cancer treatment. Clin Cancer Res. 2015;21(13):2905–2910.
   PubMed Web of Science ®Google Scholar
• Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastomaCDK4/6 inhibition in neuroblastoma. Clin Cancer Res. 2013;19(22):6173–6182.
   PubMed Web of Science ®Google Scholar
• Shaker ME, Ghani A, Shiha GE, Ibrahim TM, Mehal WZ. Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. Biochim Biophys Acta. 2013;1833(8):1992–2003.
   PubMed Web of Science ®Google Scholar
• Xu L, Jiao J, Sun X, Sang W, Gao X, Yang P, Yan D, Song X, Sun C, Liu M, et al. Cladribine induces ATF4 mediated apoptosis and synergizes with SAHA in diffuse large B-cell lymphoma cells. Int J Med Sci. 2020;17(10):1375–1384.
   PubMed Web of Science ®Google Scholar
• Ma J, Wang S, Zhao M, Deng X-S, Lee C-K, Yu X-D, Liu B. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer. 2011;11(1):255.
   PubMedGoogle Scholar
• Rollas S, Gulerman N, Erdeniz H. Synthesis and antimicrobial activity of some new hydrazones of 4-fluorobenzoic acid hydrazide and 3-acetyl-2, 5-disubstituted-1, 3, 4-oxadiazolines. Farmaco. 2002;57(2):171–174.
   PubMedGoogle Scholar
• Imramovský A, Polanc S, Vinsová J, Kocevar M, Jampílek J, Recková Z, Kaustová J. A new modification of anti-tubercular active molecules. Bioorg Med Chem. 2007;15(7):2551–2559.
   PubMed Web of Science ®Google Scholar
• Janin YL. Antituberculosis drugs: ten years of research. Bioorg Med Chem. 2007;15(7):2479–2513.
   PubMed Web of Science ®Google Scholar
• Taher AT, Helwa AA. Novel pyrimidinone derivatives: synthesis, antitumor and antimicrobial evaluation. Chem Pharm Bull . 2012;60(4):521–530.
   PubMed Web of Science ®Google Scholar
• Nasser AA, Eissa IH, Oun MR, El-Zahabi MA, Taghour MS, Belal A, Saleh AM, Mehany ABM, Luesch H, Mostafa AE, et al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Org Biomol Chem. 2020;18(38):7608–7634.
   PubMed Web of Science ®Google Scholar
• Mohamed MM, Khalil AK, Abbass EM, El-Naggar AM. Design, synthesis of new pyrimidine derivatives as anticancer and antimicrobial agents. Synth Commun. 2017;47(16):1441–1457.
   Web of Science ®Google Scholar
• Taher AT, Abou-Seri SM. Synthesis and bioactivity evaluation of new 6-aryl-5-cyano thiouracils as potential antimicrobial and anticancer agents. Molecules. 2012;17(8):9868–9886.
   PubMed Web of Science ®Google Scholar
• Helwa AA, Gedawy EM, Taher AT, Ed El-Ansary AK, Abou-Seri SM. Synthesis and biological evaluation of novel pyrimidine-5-carbonitriles featuring morpholine moiety as antitumor agents. Future Med Chem. 2019;12(5):403–421.
   Web of Science ®Google Scholar
• Luo Y, Deng Y-Q, Wang J, Long Z-J, Tu Z-C, Peng W, Zhang J-Q, Liu Q, Lu G. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors. Eur J Med Chem. 2014;78:65–71.
   PubMed Web of Science ®Google Scholar
• Kilic-Kurt Z, Ozmen N, Bakar-Ates F. Synthesis and anticancer activity of some pyrimidine derivatives with aryl urea moieties as apoptosis-inducing agents. Bioorg Chem. 2020;101:104028.
   PubMed Web of Science ®Google Scholar
• Ma L-Y, Pang L-P, Wang B, Zhang M, Hu B, Xue D-Q, Shao K-P, Zhang B-L, Liu Y, Zhang E, et al. Design and synthesis of novel 1, 2, 3-triazole-pyrimidine hybrids as potential anticancer agents. Eur J Med Chem. 2014;86:368–380.
   PubMed Web of Science ®Google Scholar
• Yang F, Yu L-Z, Diao P-C, Jian X-E, Zhou M-F, Jiang C-S, You W-W, Ma W-F, Zhao P-L. Novel [1, 2, 4] triazolo [1, 5-a] pyrimidine derivatives as potent antitubulin agents: design, multicomponent synthesis and antiproliferative activities. Bioorg Chem. 2019;92:103260.
   PubMed Web of Science ®Google Scholar
• Li Z-H, Yang D-X, Geng P-F, Zhang J, Wei H-M, Hu B, Guo Q, Zhang X-H, Guo W-G, Zhao B, et al. Design, synthesis and biological evaluation of [1, 2, 3] triazolo [4, 5-d] pyrimidine derivatives possessing a hydrazone moiety as antiproliferative agents. Eur J Med Chem. 2016;124:967–980.
   PubMed Web of Science ®Google Scholar
• Tarantelli C, Argnani L, Zinzani PL, Bertoni F. PI3Kδ Inhibitors as Immunomodulatory agents for the treatment of lymphoma patients. Cancers . 2021;13(21):5535.
   PubMed Web of Science ®Google Scholar
• Robak T, Witkowska M, Smolewski P. The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions. Cancers . 2022; 14(3):771.
   PubMed Web of Science ®Google Scholar
• Carrera AC, Anderson R. The cell biology behind the oncogenic PIP3 lipids. J Cell Sci. 2019;132(1):jcs228395. PMID: 30602575.
   PubMed Web of Science ®Google Scholar
• Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol. 2015; 23:98–107.
   PubMed Web of Science ®Google Scholar
• Kong DX, Yamori T. ZSTK474, a novel phosphatidylinositol 3- kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin. 2010;31(9):1189–1197.
   PubMed Web of Science ®Google Scholar
• Bauer TM, Patel MR, Infante JR. Targeting PI3 kinase in cancer. Pharmacol Ther. 2015;146:53–60.
   PubMed Web of Science ®Google Scholar
• McNamara CR, Degterev A. Small-molecule inhibitors of the PI3K signaling network. Future Med Chem. 2011;3(5):549–565.
   PubMed Web of Science ®Google Scholar
• Elmenier FM, Lasheen DS, Abouzid KAM. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Eur J Med Chem. 2019;183:111718.
   PubMed Web of Science ®Google Scholar
• Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2008;1784(1):159–185.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195–203.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Burger JA. PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL). Curr Top Microbiol Immunol. 2016; 393:123–142.
   PubMed Web of Science ®Google Scholar
• Burger JA, Okkenhaug K. Haematological cancer: Idelalisib-targeting PI3Kdelta in patients with B-cell malignancies. Nat Rev Clin Oncol. 2014;11(4):184–186.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005 ;30(4):194–204. PMID: 15817396.
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, et al. PI3Kγ is a molecular switch that controls immune suppression. Nature. 2016; 539(7629):437–442.
   PubMed Web of Science ®Google Scholar
• Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science. 2000; 287(5455):1049–1053. PMID: 10669418.
   PubMed Web of Science ®Google Scholar
• Ramadani F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, Corcoran AE, Okkenhaug K. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal. 2010; 3(134):ra60.
   PubMed Web of Science ®Google Scholar
• Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, Vanhaesebroeck B. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood. 2006;107(2):642–650.
   PubMed Web of Science ®Google Scholar
• Fruman DA. Targeting PI3K-Gamma in non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):932–934.
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550–562.
   PubMed Web of Science ®Google Scholar
• Zhu W, Sun C, Xu S, Wu C, Wu J, Xu M, Zhao H, Chen L, Zeng W, Zheng P, et al. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors. Bioorg Med Chem. 2014;22(24):6746–6754.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Abou-Seri SM, Hanna MM, Abdalla MM, El Sayed NA. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors. Eur J Med Chem. 2015;99:1–13.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang W, Sun C, Wang C, Zhu W, Zheng P. Synthesis and biological evaluation of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing phenylpyridine/phenylpyrimidine-carboxamides. Molecules. 2016; 21(11):1447–1458.
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S-i, Raynaud FI, et al. Synthesis and biological evaluation of pyrido[3’,2’:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3kinase p110alpha inhibitors. Bioorg Med Chem Lett. 2007;17(9):2438–2442.
   PubMed Web of Science ®Google Scholar
• Zhu WF, Zhai X, Li S, Cao YY, Gong P, Liu YJ. Synthesis and cytotoxic activity of novel 2,6-disubstituted-4-morpholinothieno[3,2-d]pyrimidines as potent anti-tumor agents. Chin Chem Lett. 2012;23(6):703–706.
   Web of Science ®Google Scholar
• Li T, Wang J, Wang X, Yang N, Chen S-M, Tong L-J, Yang C-H, Meng L-H, Ding J. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J Pharmacol Exp Ther. 2010;334(3):830–838.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012; 30(3):282–290.
   PubMed Web of Science ®Google Scholar
• Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F, Talarico G, Foà R, Bertolini F, Amadori S, et al. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Sci Rep. 2015;5(1):18137.
   PubMedGoogle Scholar
• Martínez González S, Hernández AI, Varela C, Rodríguez-Arístegui S, Alvarez RM, García AB, Lorenzo M, Rivero V, Oyarzabal J, Rabal O, et al. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. Bioorg Med Chem Lett. 2012; 22(5):1874–1878.
   PubMed Web of Science ®Google Scholar
• Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77–86.
   PubMed Web of Science ®Google Scholar
• Patil DR, Salunkhe SM, Deshmukh MB, Anbhule PV. One step synthesis of 6-amino-5-cyano-4-phenyl-2-mercapto pyrimidine using phosphorus pentoxide. TOCATJ. 2010;3(1):83–86.
   Google Scholar
• Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RS, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988;31(12):2235–2246.
   PubMed Web of Science ®Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res. 1995;34(2):91–109.
   Web of Science ®Google Scholar
• Kalalbandi VKA, Seetharamappa J, Katrahalli U, Bhat KG. Synthesis, crystal studies, anti-tuberculosis and cytotoxic studies of 1-[(2E)-3-phenylprop-2-enoyl]-1H-benzimidazole derivatives. Eur J Med Chem. 2014;79:194–202.
   PubMed Web of Science ®Google Scholar
• Abdelnaby RM, El-Malah AA, FakhrEldeen RR, Saeed MM, Nadeem RI, Younis NS, Abdel-Rahman HM, El-Dydamony NM. In vitro anticancer activity screening of novel fused thiophene derivatives as VEGFR-2/AKT dual inhibitors and apoptosis inducers. Pharmaceuticals. 2022;15(6):700.
   Web of Science ®Google Scholar
• Darzynkiewicz Z, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol. 2001;38(2):179–193.
   PubMed Web of Science ®Google Scholar
• Sharma D, Mishra A. Apoptosis induction in leukemic cells by L-asparaginase preparation from Bacillus indicus: bench-scale production, purification and therapeutic application. 3 Biotech. 2023;13(1):21.
   PubMedGoogle Scholar
• Yu RMC, Selvarajah GT, Tan GC, Cheah YK. In vitro growth inhibition, caspase-dependent apoptosis, and S and G2/M phase arrest in breast cancer cells induced by fluorine-incorporated gold I compound, Ph3PAu [SC (OMe)= NC6H4F-3]. Int J Breast Cancer. 2022;2022:1–18.
   Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.
   PubMed Web of Science ®Google Scholar
• Khalilzadeh B, Shadjou N, Afsharan H, Eskandani M, Charoudeh HN, Rashidi MR. Reduced graphene oxide decorated with gold nanoparticle as signal amplification element on ultra-sensitive electrochemiluminescence determination of caspase-3 activity and apoptosis using peptide based biosensor. Bioimpacts. 2016;6(3):135–147.
   PubMedGoogle Scholar
• Aborehab NM, Elnagar MR, Waly NE. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021;35(2):e22638.
   PubMed Web of Science ®Google Scholar
• Burnette WN. Western blotting: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981;112(2):195–203.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Trott O, Olso AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.
   PubMed Web of Science ®Google Scholar
• Liu C, Li D, Xing G, Chen L, Lin M, Ling Q. Synthesis and properties of main-chain phosphorescent polymer with iridium complex. Russ J Gen Chem. 2019;89(12):2504–2511.
   Web of Science ®Google Scholar
• Mohamed KS, Elbialy EE, Fadda AA. Application of N-(Aryl)-2-oxo-2-(arylamino) acetohydrazonoyl cyanide in synthesis of some novel triazole derivatives and their biological activity. Russ J Gen Chem. 2021;91(8):1592–1603.
   Web of Science ®Google Scholar
• Rostamizadeh S, Nojavan M, Aryan R, Sadeghian H, Davoodnejad M. A novel and efficient synthesis of pyrazolo [3, 4-d] pyrimidine derivatives and the study of their anti-bacterial activity. Chinese Chem Lett. 2013;24(7):629–632.
   Web of Science ®Google Scholar
• Szőcs B, Bokor É, Szabó KE, Kiss-Szikszai A, Tóth M, Somsák L. Synthesis of 5-aryl-3-C-glycosyl-and unsymmetrical 3, 5-diaryl-1, 2, 4-triazoles from alkylidene-amidrazones. RSC Adv. 2015;5(54):43620–43629.
   Web of Science ®Google Scholar
• Al Zoubi W, Al-Hamdani AAS, Ahmed SD, Ko YG. A new azo-Schiff base: Synthesis, characterization, biological activity and theoretical studies of its complexes. Appl Organomet Chem. 2018;32(1):3895.
   Web of Science ®Google Scholar
• Acton EM, Narayanan VL, Risbood PA, Shoemaker RH, Vistica DT, Boyd MR. Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem. 1994;37(14):2185–2189.
   PubMed Web of Science ®Google Scholar
• Chan KT, Meng FY, Li Q, Ho CY, Lam TS, To Y, Lee WH, Li M, Chu KH, Toh M. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett. 2010;294(1):118–124.
   PubMed Web of Science ®Google Scholar
• Shen JK, Du H. p, Yang M, Wang YG, Jin J. Casticin induces leukemic cell death through apoptosis and mitotic catastrophe. Ann Hematol. 2009;88(8):743–752.
   PubMed Web of Science ®Google Scholar
• Blank M, Shiloh Y. Programs for cell death: apoptosis is only one way to go. Cell Cycle. 2007;6(6):686–695.
   PubMed Web of Science ®Google Scholar
• Persad R, Liu C, Wu T-T, Houlihan PS, Hamilton SR, Diehl AM, Rashid A. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol. 2004;17(7):861–867.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz HA, Eldehna WM, Keeton AB, Piazza GA, Kadi AA, Attwa MW, Abdelhameed AS, Attia MI. Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling. Drug Des Devel Ther. Published online 2017; 11:2333–2346.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers. 2011;3(1):994–1013.
   PubMedGoogle Scholar
• Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443(7112):651–657.
   PubMed Web of Science ®Google Scholar
• Macias-Perez IM, Flinn IW. GS-1101. A delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2013; 8(1):22–27.
   PubMed Web of Science ®Google Scholar
• Rodrigues DA, Sagrillo FS, Fraga CAM. Duvelisib: a 2018 novel FDA-approved small molecule inhibiting phosphoinositide 3-kinases. Pharmaceuticals . 2019;12(2):69. 6
   Web of Science ®Google Scholar
• Erra M, Taltavull J, Bernal FJ, Caturla JF, Carrascal M, Pagès L, Mir M, Espinosa S, Gràcia J, Domínguez M, et al. Discovery of a novel inhaled PI3Kδ inhibitor for the treatment of respiratory diseases. J Med Chem. 2018;61(21):9551–9567.
   PubMed Web of Science ®Google Scholar
• Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Ren P, Liu Y, et al. The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol. 2010;6(2):117–124.
   PubMed Web of Science ®Google Scholar
• Williams O, Houseman BT, Kunkel EJ, Aizenstein B, Hoffman R, Knight ZA, Shokat KM. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs. Chem Biol. 2010;17(2):123–134.
   PubMedGoogle Scholar
• Cushing TD, Hao X, Shin Y, Andrews K, Brown M, Cardozo M, Chen Y, Duquette J, Fisher B, Gonzalez-Lopez de Turiso F, et al. Discovery and in vivo evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease. J Med Chem. 2015;58(1):480–511.
   PubMed Web of Science ®Google Scholar